SMSLIFE2024-04-012024-06-30 SMSLIFE2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member SMSLIFE2024-04-012024-06-30in-bse-fin:OneOperatingExpenses02Member SMSLIFE2024-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 540679 SMSLIFE NOTLISTED SMS Lifesciences India Limited Equity 2024-04-01 2025-03-31 2024-08-09 2024-08-06 INR Lakhs First quarter 13:15:00 14:35:00 2024-08-09 2024-08-09 Not applicable Single segment Bulk Drugs / API's 2024-04-01 2024-06-30 Unaudited Consolidated 925482000.00 4392000.00 929874000.00 427212000.00 0.00 5956000.00 143791000.00 24048000.00 36787000.00 185677000.00 823471000.00 106403000.00 0.00 106403000.00 31200000.00 4240000.00 35440000.00 0.00 70963000.00 0.00 0.00 0.00 0.00 70963000.00 -1250000.00 69713000.00 69981000.00 982000.00 68778000.00 935000.00 30233000.00 10 23.15 23.15 0.00 0.00 23.15 23.15 Notes: 1. The above Consolidated Financial Results have been reviewed and recomended by the Audit Committee on 09th August, 2024 and have been approved by the Board of Directors at its meeting held on 09th August, 2024.The statutory auditors of the Company have carriedout the a limited review of Consolidated financial results for the quarter ended 30th June, 2024 and expressed unmodified conclusion thereon. 2. The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ( Ind AS ) prescribed under section 133 of the Companies Act, 2013 ( the Act ) read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The figures for quarter ended 31st March, 2024 are balancing figures between audit figures of the full financial year ended 31st March, 2024 and the published year to date figures upto third quarter ended 31st December, 2023. Hence the current Quarter figures are not comparable with previous Quarter. 4. The Consolidated financial results are prepared by applying Ind AS-110 Consolidated Financial Statements , includes financial results of Mahi Drugs Private Limited, a subsidiary with 60% stake. 5. The Consolidated entity is engaged in manufacturing Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108. 6. Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification. Manufacturing Expenses 163359000.00 Other Expenses 22318000.00 1756000.00 -506000.00